NEW YORK, May 22, 2017 /PRNewswire/ --
Stock-Callers.com has issued today's research reports on: Editas Medicine Inc. (NASDAQ: EDIT), Global Blood Therapeutics Inc. (NASDAQ: GBT), Geron Corp. (NASDAQ: GERN), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Biotech companies produce medicine that have a biological basis, use live organisms or their products to manufacture their drugs, and have more applications than pharmaceutical companies. These stocks research reports can be downloaded now by simply registering for free at: http://stock-callers.com/registration
Cambridge, Massachusetts-based Editas Medicine Inc.'s shares dropped 4.38%, finishing last Friday's session at $17.91. A total volume of 514,487 shares was traded. The stock has advanced 10.35% since the start of this year. The Company's shares are trading below their 200-day moving average by 1.48%. Additionally, shares of Editas Medicine, which operates as a genome editing company, have a Relative Strength Index (RSI) of 42.71.
On May 13th, 2017, Editas Medicine announced results from a pre-clinical study demonstrating the first achievement of efficient editing of the CEP290 gene in the retina of non-human primates. The results of this study further reinforce the Company's belief in the transformative potential of its candidate medicine for Leber Congenital Amaurosis type 10 (LCA10), an inherited retinal degenerative disease that appears in childhood and leads to blindness. Your complete research report on EDIT can be retrieved for free at: http://stock-callers.com/registration/?symbol=EDIT
Global Blood Therapeutics
On Friday, shares in South San Francisco, California headquartered Global Blood Therapeutics Inc. ended the session 1.65% lower at $29.75. The stock recorded a trading volume of 430,633 shares. The Company's shares have gained 10.59% in the previous three months and 105.88% on an YTD basis. The stock is trading above its 200-day moving average by 31.58%. Moreover, shares of Global Blood Therapeutics, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 42.91.
On May 18th, 2017, Global Blood Therapeutics announced that new data supporting its GBT440 program in sickle cell disease will be presented at the upcoming 22nd Congress of the European Hematology Association, which will be held from June 22nd, 2017 to June 25th, 2017 in Madrid. The poster presentation will highlight preliminary results from the single-dose arm of the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study of GBT440 in adolescents ages 12 to 17. A free report on GBT is just a click away at: http://stock-callers.com/registration/?symbol=GBT
Menlo Park, California-based Geron Corp.'s stock declined 0.33%, to close the day at $3.05 with a total trading volume of 1.28 million shares. The Company's shares have advanced 26.03% in the last one month, 33.77% over the previous three months, and 47.34% since the start of this year. The stock is trading 27.19% above its 50-day moving average and 33.94% above its 200-day moving average. Additionally, shares of Geron, which operates as a biopharmaceutical company, have an RSI of 72.11.
On May 09th, 2017, Geron reported financial results for Q1 ended March 31st, 2017. Operating revenues were $537,000 and operating expenses were $8.0 million for the quarter. Net loss for Q1 2017 was $7.2 million; R&D expenses were $3.4 million; general and administrative expenses were $4.7 million; and interest and other income were $332,000. Additionally, the Company ended Q1 2017 with $121.7 million in cash and investments. Sign up for your complimentary research report on GERN at: http://stock-callers.com/registration/?symbol=GERN
Shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. recorded a trading volume of 696,493 shares. The stock ended at $1.78, jumping 4.71% from the last trading session. The Company's shares have gained 31.85% on an YTD basis. The stock is trading below its 200-day moving average by 3.41%. Furthermore, shares of Infinity Pharma, which develops medicines for patients with difficult-to-treat diseases in the US, have an RSI of 37.56.
On May 09th, 2017, Infinity Pharma announced its Q1 2017 financial results. At March 31st, 2017, the Company had total cash, cash equivalents, and available-for-sale securities of $75.4 million. R&D expense for Q1 2017 was $4.0 million, general and administrative expense was $6.4 million, and net loss was $10.5 million. Register for free on Stock-Callers.com and download the latest research report on INFI at: http://stock-callers.com/registration/?symbol=INFI
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA